• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Chromadex Corp CS (NQ: CDXC )

    2.710 -0.040 (-1.45%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 236,821
    Open 2.800
    Bid (Size) 2.710 (7)
    Ask (Size) 2.720 (3)
    Prev. Close 2.750
    Today's Range 2.710 - 2.890
    52wk Range 1.250 - 4.650
    Shares Outstanding 68,196,526
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
    From ChromaDex Corporation
    Via Business Wire

    Performance

    YTD
    +89.51%
    +89.51%
    1 Month
    -14.24%
    -14.24%
    3 Month
    -15.31%
    -15.31%
    6 Month
    +86.90%
    +86.90%
    1 Year
    +69.37%
    +69.37%

    More News

    Read More
    CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023
    Via InvestorPlace
    Earnings Preview For ChromaDex
    Via Benzinga
    Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
    From ChromaDex Corporation
    Via Business Wire
    CDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    ChromaDex Corporation Reports First Quarter 2024 Financial Results
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
    From ChromaDex Corporation
    Via Business Wire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
    From ChromaDex Corporation
    Via Business Wire
    Earnings Scheduled For March 6, 2024
    Via Benzinga
    ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
    From ChromaDex Corporation
    Via Business Wire
    ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
    From ChromaDex Corporation
    Via Business Wire
    A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
    From ChromaDex Corporation
    Via Business Wire
    Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
    From ChromaDex Corporation
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.